Pennant Investors, LP Replimune Group, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 30,500 shares of REPL stock, worth $369,355. This represents 0.07% of its overall portfolio holdings.
Number of Shares
30,500
Previous 30,500
-0.0%
Holding current value
$369,355
Previous $249,000
10.04%
% of portfolio
0.07%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding REPL
# of Institutions
155Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$122 Million1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.24MShares$112 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$67.4 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$58.9 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$57.1 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $597M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...